NCT04039087View on ClinicalTrials.gov

Sildenafil Exercise: Role of PDE5 Inhibition

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Cystic Fibrosis
Interventions
DRUG

Sildenafil 40mg oral capsule

40 mg, sildenafil capsule taken by mouth thrice daily

DRUG

Placebo Oral capsule

Placebo capsule taken by mouth thrice daily

Trial Locations (2)

30912

Augusta University, Augusta

80206

National Jewish Health, Denver

All Listed Sponsors
collaborator

Augusta University

OTHER

collaborator

Cystic Fibrosis Foundation

OTHER

lead

National Jewish Health

OTHER

NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition | Biotech Hunter | Biotech Hunter